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Abstract
The prevalence of affective disorders such as depression and 
anxiety is particularly high in patients with autoimmune dis-
eases, including inflammatory skin diseases such as psoria-
sis, atopic dermatitis, and hidradenitis suppurativa. A dys-
regulated immune response has been linked to the precipi-
tation of depression in many patient populations. However, 
studies examining the extent to which the underlying skin 
disease inflammatory processes contribute to depression 
and a subsequent decline in quality of life are limited. The 
published literature over the past 5 years was reviewed for 
evidence of a relationship between depression and inflam-
matory processes in the context of skin pathology. The find-
ings, particularly the evidence from interventional clinical 
trials of targeted anti-cytokine therapies, suggest that pro-
inflammatory cytokines associated with several skin diseases 
may be causally linked with the coexistent depressive symp-
tomology. © 2018 S. Karger AG, Basel
Introduction
The prevalence of affective disorders in dermatologi-
cal patients is high [1]. Approximately 30% of patients 
with skin disorders suffer from a comorbid psychological 
condition [2, 3], such as depression, anxiety, and somati-
zation [1]. Chronic inflammatory skin diseases such as 
psoriasis (PS), atopic dermatitis (AD), and hidradenitis 
suppurativa (HS) are particularly debilitating skin disor-
ders which have a heavy psychological burden [4–6]. The 
disability reported in cases of PS is comparable to illness-
es such as cancer and coronary artery disease [7].
Depression is reported in up to 42% of patients with 
HS in the USA, and in a large study involving 3,207 pa-
tients, there was an odds ratio of 1.7 for depression in 
people living with HS compared to other dermatological 
patients [8, 9]. In another study on 154 patients with HS, 
depressive symptoms were reported in more than 70% of 
the cases; 55 patients (34.7%) had depression and 32 
(20.8%) had borderline depressive symptoms [10].
Patients with AD and HS experience high suicidality 
according to several studies [11, 12]. However, it should 
be noted that a recent systematic review on the risk of sui-
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cidality in PS patients found no increased risk in suicide 
among these patients [13]; the low methodological qual-
ity for the included studies warrants further research. 
Huilaja et al. [14] reported the psychological burden of 
HS in a large Finnish study, with at least 1 psychiatric dis-
order in 24% of HS patients, compared to 19% of the pa-
tients with PS and 13.5% with dysplastic nevus. 
It is difficult to decipher the extent to which depressive 
symptoms present in patients with these dermatological 
disorders is due to the underlying cutaneous inflamma-
tory disease compared to the psychosocial impact of liv-
ing with chronic illness. The disfiguring and visible na-
ture of chronic inflammatory skin diseases undoubtedly 
contributes to their psychosocial impact; however, the 
prevalence of depression in PS, for example, is higher 
than similarly disfiguring skin disorders such as ichthyo-
sis [4]. The aim of this study is to review the recent litera-
ture for the evidence of a relationship between depression 
and the underlying inflammatory processes characterized 
in PS, AD, and HS [4]. These proposed relationships are 
outlined in Figure 1.
Materials and Methods
A search of the PubMed, PsycINFO, and Cochrane databases 
was conducted for any relevant English articles published from 
2012 to 2017, using the following terms: (inflammation OR inflam-
matory OR cytokine) AND (depression OR mood OR psych*) 
AND (skin OR derm*) AND (atopic dermatitis OR hidradenitis 
suppurativa OR psoriasis). Moreover, reference lists of any review, 
meta-analysis and related articles as well as clinical trial registries 
were searched for any missing published and unpublished studies. 
There were 240 records from this search which were combined 
with hand searches, to result in 273 entries. Duplicates, non-Eng-
lish articles, and animal studies were excluded. A breakdown of the 
total search for each disease included 46, 112, and 16 records for 
AD, PS, and HS, respectively. The relevant abstracts were re-
viewed; 42 papers were selected for full-text review and included 
in the manuscript. 
Discussion
Potential Mechanisms for a Pro-Inflammatory State 
Contributing to Psychological Effects 
There are a number of important mechanisms through 
which a pro-inflammatory state may contribute to de-
pression, including the psychological effects of circulat-
ing mediators and direct effects on the microglia. 
There are considerable data showing that elevated lev-
els of circulating cytokines can have a psychological im-
pact. Cytokines such as interleukin (IL)-6 and tumor ne-
crosis factor (TNF)-α can be detected in the serum during 
major depression, and they exhibit a dose-response rela-
tionship with the severity of depression [15, 16]. In stud-
ies where interferon immunotherapy was used for the 
treatment of viral hepatitis and cancer, increased psycho-
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logical distress including depression was provoked in pa-
tients, even in those without a psychiatric history [17, 18]. 
Furthermore, the activation of the immune system has 
been shown to induce mood changes which resemble 
sickness behaviors and overlap with the behavioral symp-
toms of depression such as anhedonia, anorexia, and so-
cial withdrawal [19]. Reichenberg et al. [20] investigated 
the effects of low-dose endotoxemia on emotional and 
cognitive function, and found that following an endotox-
in injection, there is a transient increase in the levels of 
anxiety and depressive symptoms and a decrease in mem-
ory performance, measured using the state anxiety inven-
tory, the depression adjectives check list, and a battery of 
neuropsychological tests, respectively. 
Although inflammation may be local, arising in pe-
ripheral organs, pro-inflammatory cytokines such as 
TNF-α and IL-6, but also dendritic cells, can cross the 
blood-brain barrier (BBB) and trigger a cascade of events 
in the central nervous system [21]. The integrity of the 
BBB can be compromised due to stress, leading to a “leaky 
BBB” which does not adequately protect the brain from 
peripheral cytokine infiltration [22]. An overactive stress 
response [23] and elevated levels of peripheral cytokines 
can lead to brain cytokine signaling with downstream ef-
fects on synaptic function via the actions of the microglia, 
neurotransmitter metabolism, and neurogenesis [22]. 
For example, increased levels of TNF-α accelerate the 
breakdown of neurotransmitters, such as serotonin, by 
increasing the activity of the enzyme indoleamine 2,3-di-
oxygenase [24]. Furthermore, central inflammation has 
also been associated with oxidative stress and reduced 
neurogenesis in several brain regions which are implicat-
ed in depression including the hippocampus [25–27]. 
Therefore, the bidirectional relationship between psy-
chological stress and physiological inflammatory re-
sponses may be a precipitating factor for depression and 
further inflammation in vulnerable individuals.
Dysregulation of the Hypothalamic-Pituitary-Adrenal 
Axis May Have Neurological Effects
The nervous system and skin interact via the actions of 
hypothalamic-pituitary-adrenal (HPA)-axis hormones 
and the upregulation of substance P and calcitonin gene-
related peptide amongst others [28]. The HPA axis con-
sists of hypothalamic corticotropin-releasing hormone 
(CRH) stimulating the release of pituitary adrenocortico-
tropic hormone (ACTH), which then stimulates the pro-
duction of cortisol by the adrenal glands. Appropriate 
HPA axis reactivity to stressful stimuli is necessary to 
control immunological responses [29]. 
CRH has been shown to stimulate the local cutaneous 
production of cytokines and the keratinocyte expression 
of immune cell adhesion molecules [4]. Biopsies of psori-
atic lesions show increased expression of CRH, suggest-
ing that it plays a role in the pathophysiology of the dis-
ease and possibly in skin-brain interactions [30]. TNF-α 
administration elevates plasma levels of ACTH and cor-
tisol [31]. IL-6 can increase ACTH and cortisol, amplify-
ing systemic pro-inflammatory circuits [32]. A chronic 
state of elevated levels of ACTH and cortisol can lead to 
glucocorticoid receptor insensitivity and an overall dys-
regulation of HPA pathways [33].
Interactively, psychological stress can increase the lev-
els of cortisol and inflammatory cytokines [25, 34]. PS, 
AD, and HS have been observed to worsen in response to 
psychological stress [35, 36]. Patients with stress-reactive 
PS (PS that worsens during periods of stress) exhibit a 
blunted HPA axis response to acute social stressors as 
measured by serum cortisol levels [34]. Interestingly, it is 
social stress rather than cognitive or emotional stress that 
is discriminative in stress-reactive PS [34]. Hence, dys-
regulation of the HPA axis may contribute to inflamma-
tory, physiological, and neurological effects.
Evidence for an Association of Skin Disease with 
Cognitive Impairment
It has been shown that PS patients may suffer from cog-
nitive impairment [37–39]. For instance, a recent study on 
patients with severe PS revealed that they scored lower in 
neuropsychological tests that assessed working memory 
and executive function (e.g., the trail-making test, the 
Stroop color-word interference test, and the Beck Depres-
sion Inventory [BDI]) than a healthy control group and 
independently of depressive symptom severity [37]. In the 
same study, a longer duration of PS significantly corre-
lated with worse outcomes on measures of working mem-
ory and executive function. This may be suggestive of the 
adverse effects of chronic inflammation on the prefrontal 
cortex which supports important cognitive processes such 
as decision-making and attention [37]. In a study on AD 
patients, cortisol, ACTH, and catecholamine concentra-
tions were assessed before and after a stressful task (the 
Trier social stress test) to investigate the sensitivity of the 
HPA axis. The AD patients showed significantly attenu-
ated cortisol and ACTH responses to stress [29]. 
HS is also a chronic, debilitating disease with a strong 
link to anxiety, depression, and substance abuse [40]. A 
cross-sectional study found that the individuals with HS 
(n = 94) reported significantly higher anxiety scores than 
the healthy controls, and that higher disease severity (Hur-
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ley stage III) was associated with higher anxiety levels [41]. 
In a recent study, the psychological trait of resilience, the 
ability to adapt well to adversity, moderated depression in 
HS, such that greater resilience was associated with lower 
depressive symptoms in HS patients [10]. Although, to the 
best of our knowledge, studies examining stress responses 
have not been conducted on HS patients, comorbidity 
with several endocrine disorders such as diabetes, acro-
megaly and Cushing’s disease suggest that similar endo-
crine disruptions may play a role in HS [42].
The Skin as a Source of Pro-Inflammatory Mediators
An important driver of pathogenesis in many inflam-
matory skin disorders is the activation of cutaneous T 
cells and dendritic cells and the upregulation of pro-in-
flammatory cytokines. Following migration to the skin 
and the release of pro-inflammatory cytokines, immune 
cells promote biological responses in keratinocytes which 
themselves are instigators of further inflammation [43]. 
Genome-wide comparative analyses report a high degree 
of genomic coincidence between PS and AD; however, 
opposing risk alleles and independent disease-specific 
loci within the epidermal differentiation complex and 
other regions have been identified that influence immune 
response [44]. 
It is now appreciated that each of these skin diseases, 
PS, AD, and HS, has a distinctive cytokine signature [45, 
46]. PS is dominated by upregulation of the IL-17 axis, but 
with contributions from excess IL-12/23 and TNF-α [47]. 
IL-36 mutations have recently been discovered in some 
subtypes of PS [48]. Skin biopsies from AD sufferers show 
a predominance of T-helper-2-derived cytokines; it is 
suggested that this contributes to the mechanism of 
stress-induced inflammation in AD [29]. Recent effective 
targeted therapy directed at the IL-4/13 axis has demon-
strated the importance of this pathway in AD [49]. The 
cytokine signature in HS is not fully elucidated, but may 
include dysregulation of TNF, IL-1, IL-12/23, IL-17, and 
IL-6 [50]. As discussed above, cytokines such as IL-6 and 
TNF-α may contribute to central nervous system changes 
and microglial remodeling [15].
Evidence for Psychological Effects in Immune-
Modulating Interventional Clinical Trials for PS, AD, 
and HS
Certain targeted therapeutic interventions directed at 
inflammatory skin diseases like PS, AD, and HS have in-
vestigated concurrent psychological effects. A phase 3 
study of placebo or etanercept (50 mg twice weekly), a 
soluble TNF-α receptor, in patients with PS (n = 618) has 
indicated meaningful improvement in symptoms of de-
pression as measured by the Hamilton Depression Rating 
Scale (HAM-D) and BDI at week 12 [51]. Patients with 
moderate-to-severe PS (n = 1,230) receiving 90 mg of 
ustekinumab, a human IL-12/23 antibody, in a phase 3 
clinical trial, showed significant improvement in symp-
toms of depression as measured by the Hospital Anxiety 
and Depression Scale (HADS) at week 12, when com-
pared with placebo [52]. The use of adalimumab (n = 44, 
40 mg every other week), a human monoclonal IgG1 an-
tibody against TNF, versus placebo (n = 52), in moderate-
to-severe PS, resulted in a substantial reduction in de-
pressive symptoms, as measured by the Zung Self-Rating 
Depression Scale (ZDS) after 12 weeks [53]. In 2 random-
ized placebo-controlled phase 3 studies of dupilumab, a 
monoclonal antibody that binds specifically to the shared 
α-chain subunit of the IL-4 and IL-13 receptors, symp-
toms of depression and anxiety (measured by HADS) 
were reduced significantly in patients with moderate and 
severe AD [54, 55]. The alleviation of pain by targeting 
inflammation in HS patients using adalimumab has also 
been shown to reduce depressive symptoms and pain 
scores [56]. 
Opportunities for Interventions
Figure 1 summarizes the potential relationship be-
tween skin-derived inflammatory mediators negatively 
impacting psychological well-being, and depression lead-
ing to increased skin inflammation, which creates a 
chronic exacerbating cycle. The interaction between psy-
chological factors and inflammation suggest that inter-
ventions targeted at improving either aspect of the disease 
can help improve patients’ quality of life. Indeed, inter-
rupting any of these elements may help improve both skin 
inflammation and depressive psychological symptoms. 
Importantly, studies on the effects of biologics (TNF 
or cytokine inhibitors) for patients with PS and AD report 
that these treatments are associated with significant re-
ductions in depressive symptoms, as discussed above [3, 
54]. Randomized controlled trials of the use of anti-in-
flammatory agents and cytokine inhibitors for the treat-
ment of depression in nondermatological patients show 
similar results [57]. These observations demonstrate that 
pro-inflammatory cytokines specifically targeted by dis-
ease-modulating anti-cytokine therapies have a beneficial 
impact on psychological comorbidities such as depres-
sion. Physical metrics of disease severity, in conjunction 
with subjective patient-reported outcomes such as pain 
and depression, should therefore be a continued focus of 
therapeutic outcomes. In addition, evidence exists to 
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show that anti-depressant treatment, particularly sero-
tonin reuptake inhibitors, reduces levels of IL-6 and 
TNF-α [58]. However, the exact molecular mechanisms 
and signaling pathways underlying the association of de-
pression with inflammatory skin disease remain incom-
pletely understood. 
Anti-inflammatory pharmacological agents targeting 
the skin have shown effectiveness in improving inflam-
matory symptoms, depressive symptoms, and overall 
quality of life in PS and AD. There is a scarcity of research 
into psychological outcomes following treatment with 
anti-inflammatory agents in HS and AD, in addition to 
considering adjunctive psychological interventions in 
these patient populations.
In conclusion, the reviewed literature is supportive of 
an approach to management which accounts for the com-
plex interaction between psychological and physiological 
factors in inflammatory conditions, with particular atten-
tion to improving the psychological burden of these dis-
orders. The bidirectional relationship between psycho-
logical stress and physiological inflammatory responses 
may be a plausible conduit for the precipitation or exac-
erbation of depression and further cutaneous inflamma-
tion in vulnerable individuals. 
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